Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
- During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
- Cocrystal utilizes a proprietary structure-based technology platform to discover viral inhibitors that address underserved medical needs in very large markets including pandemics and widespread viral infections, said Sam Lee, Ph.D., interim co-CEO and President.
- This powerful platform differentiates Cocrystals approach and allows us to focus on three important drug-discovery processes including improvements with in vitro potency, broad-spectrum activity and drug-resistance profile.
- Given our cost-efficient structure and financial resources, we believe we have sufficient capital to fund current operations and planned program activities through 2024.